Medigene AG (WBO:MDG1) ROCE % : -57.02% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Medigene AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medigene AG's annualized ROCE % for the quarter that ended in Dec. 2023 was -57.02%.

Medigene AG ROCE % Historical Data

The historical data trend for Medigene AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG ROCE % Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-18.10

-34.20

-17.09

-18.21

-46.64

Medigene AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-16.27	48.30	-81.96	-36.61	-57.02

Medigene AG ROCE % Calculation

Medigene AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-16.044	/	( ( (51.678 - 7.415)	+	(31.716 - 7.179) )	/ 2 )
	=	-16.044	/	( (44.263	+	24.537)	/ 2 )
	=	-16.044	/	34.4
	=	-46.64 %

Medigene AG's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-17.342	/	( ( (42.177 - 5.885)	+	(31.716 - 7.179) )	/ 2 )
	=	-17.342	/	( ( 36.292	+	24.537 )	/ 2 )
	=	-17.342	/	30.4145
	=	-57.02 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Medigene AG (WBO:MDG1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medigene AG ROCE % Related Terms

Thank you for viewing the detailed overview of Medigene AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigene AG (WBO:MDG1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (WBO:MDG1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MDGEF:USA MDG1:Germany

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG (WBO:MDG1) Headlines

No Headlines